Zinc: Indications in brain disorders

Fundamental and Clinical Pharmacology

Volumn 29, Issue 2, 2015, Pages 131-149

  Prakash, Atish ^a,b   Bharti, Kanchan ^b   Majeed, Abu Bakar A ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

Alzheimer's disease; Depression; Epilepsy; Neurotoxicity; Prion disease; Stroke; Zinc

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; NEUROTROPHIN; PRION PROTEIN; SEROTONIN; ZINC; ZINC TRANSPORTER; CATION TRANSPORT PROTEIN; SLC30A3 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN DEVELOPMENT; BRAIN DISEASE; BRAIN FUNCTION; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPILEPSY; HUMAN; HUNTINGTON CHOREA; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; SYNAPSE; TRAUMATIC BRAIN INJURY; ZINC HOMEOSTASIS; ANIMAL; BRAIN; BRAIN DISEASES; BRAIN INJURIES; HOMEOSTASIS; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; PHYSIOLOGY; STROKE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BRAIN; BRAIN DISEASES; BRAIN INJURIES; CATION TRANSPORT PROTEINS; HOMEOSTASIS; HUMANS; NEURODEGENERATIVE DISEASES; STROKE; ZINC;

EID: 84924812666     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12110     Document Type: Article

References (181)

1. Vasak M., Hasler D.W. Metallothioneins: new functional and structural insights. Curr. Opin. Chem. Biol. (2000) 4 177-183.
2. Rink L., Gabriel P. Zinc and the immune system. Proc. Nutr. Soc. (2000) 59 541-552.
3. McCall K.A., Huang C., Fierke C.A. Function and mechanism of zinc metalloenzymes. J. Nutr. (2000) 130 1437S-1446S.
4. Bhowmik D., Chiranjib ., Kumar K.P.S. A potential medicinal importance of zinc in human health and chronic disease. Int. J. Pharm. Biomed. Sci. (2010) 1 05-11.
5. Haase H., Beyersmann D. Intracellular zinc distribution and transport in C6 rat glioma cells. Biochem. Biophys. Res. Commun. (2002) 296 923-928.
6. Truong-Tran A.Q., Carter J., Ruffin R., Zalewski P.D. New insights into the role of zinc in the respiratory epithelium. Immunol. Cell Biol. (2001) 79 170-177.
7. Plum L.M., Rink L., Haase H. The essential toxin: impact of zinc on human health. Int. J. Environ. Res. Public Health (2010) 7 1342-1365.
8. 2+ dyshomeostasis. J. Trace Elem. Med Biol. (2014) 28 393-396.
9. Takeda A., Fujii H., Minamino T., Tamano H. Intracellular Zn(2+) signaling in cognition. J. Neurosci. Res. (2014) 92 819-824.
10. Lee S.J., Michel S.L. Structural metal sites in nonclassical zinc finger proteins involved in transcriptional and translational regulation. Acc. Chem. Res. (2014) 47 2643-2650.
11. Seve M., Chimienti F., Devergnas S., Favier A. In silico identification and expression of SLC30 family genes: an expressed sequence tag data mining strategy for the characterization of zinc transporters' tissue expression. BMC Genom. (2004) 5 32-36.
12. Kambe T., Yamaguchi-Iwai Y., Sasaki R., Nagao M. Overview of mammalian zinc transporters. Cell. Mol. Life Sci. (2004) 61 49-68.
13. Sindreu C., Palmiter R.D., Storm D.R. Zinc transporter ZnT-3 regulates presynaptic Erk1/2 signaling and hippocampus-dependent memory. Proc. Natl Acad. Sci. USA (2011) 108 3366-3370.
14. O'Dell B.L., Browning J.D. Impaired calcium entry into cells is associated with pathological signs of zinc deficiency. Adv. Nutr. (2013) 3 287-293.
15. Engle-Stone R., Ndjebayi A.O., Nankap M., Killilea D.W., Brown K.H. Stunting prevalence, plasma zinc concentrations, and dietary zinc intakes in a nationally representative sample suggest a high risk of zinc deficiency among women and young children in Cameroon. J. Nutr. (2014) 3 382-391.
16. Tapiero H., Tew K.D. Trace elements in human physiology and pathology: zinc and metallothioneins. Biomed. Pharmacother. (2003) 57 399-411.
17. Sharma S., Ebadi M. Significance of metallothioneins in aging brain. Neurochem. Int. (2014) 65 40-48.
18. Paoletti P., Vergnano A.M., Barbour B., Casado M. Zinc at glutamatergic synapses. Neuroscience (2009) 158 126-136.
19. Frederickson C.J., Koh J.Y., Bush A.I. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. (2005) 6 449-462.
20. 2+ antagonize NMDA and GABA responses of hippocampal neurons. Nature (1987) 328 640-643.
21. Li X., Chen Z., Jiang Z., Li Y., Zhang Y. Zinc reverses glycine-dependent inactivation of NMDARs in cultured rat hippocampal neurons. Sci. China Life Sci. (2012) 55 1075-1081.
22. Zhu J., Shao C.Y., Yang W. et al. Chronic zinc exposure decreases the surface expression of NR2A-containing NMDA receptors in cultured hippocampal neurons. PLoS One (2012) 7 e46012.
23. 2+ sensitivity of high- and low-voltage activated calcium channels. Biophys. J. (2007) 93 1175-1183.
24. Frederickson C.J., Giblin L.J. III, Balaji R.V. et al. Synaptic release of zinc from brain slices: factors governing release, imaging, and accurate calculation of concentration. J. Neurosci. Methods (2006) 154 19-29.
25. Cohen-Matsliah S.I., Brosh I., Rosenblum K., Barkai E. A novel role for extracellular signal-regulated kinase in maintaining long-term memory-relevant excitability changes. J. Neurosci. (2007) 27 12584-12589.
26. Li Y.H., Wang J., Zhang G. Involvement of synaptic NR2B-containing NMDA receptors in long-term depression induction in the young rat visual cortex in vitro. Chin. J. Physiol. (2011) 54 190-195.
27. Amico-Ruvio S.A., Paganelli M.A., Myers J.M., Popescu G.K. Ifenprodil effects on GluN2B-containing glutamate receptors. Mol. Pharmacol. (2012) 82 1074-1081.
28. Sensi S.L., Paoletti P., Bush A.I., Sekler I. Zinc in the physiology and pathology of the CNS. Nat. Rev. Neurosci. (2009) 10 780-791.
29. Bush A.I., Pettingell W.H., Multhaup G. et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science (1994) 265 1464-1467.
30. Deshpande A., Kawai H., Metherate R., Glabe C.G., Busciglio J., Gundelfinger E. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J. Neurosci. (2009) 29 4004-4015.
31. Huang Y.Z., Pan E., Xiong Z.Q., McNamara J.O. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron (2008) 57 546-558.
32. 2+ and loss of NAD+. Eur. J. Neurosci. (2010) 32 894-904.
33. Sheline C.T., Behrens M.M., Choi D.W. Zinc induced cortical neuronal death: contribution of energy failure attributable to loss of NAD+ and inhibition of glycolysis. J. Neurosci. (2000) 20 3139-3146.
34. Lemire J., Mailloux R., Appanna V.D. Zinctoxicity alters mitochondrial metabolism and leads to decreased ATP production in hepatocytes. J. Appl. Toxicol. (2008) 28 175-182.
35. He K., Aizenman E. ERK signaling leads to mitochondrial dysfunction in extracellular zinc-induced neurotoxicity. J. Neurochem. (2010) 114 452-461.
36. Park J.A., Koh J.Y. Induction of an immediate early gene egr-1 by zinc through extracellular signal-regulated kinase activation in cortical culture: its role in zinc-induced neuronal death. J. Neurochem. (1999) 73 450-456.
37. 2+ inhibits mitochondrial movement in neurons by phosphatidylinositol 3-kinase activation. J. Neurosci. (2005) 25 9507-9514.
38. Lozier E.R., Stelmashook E.V., Uzbekov R.E. et al. Stimulation of kainate toxicity by zinc in cultured cerebellar granule neurons and the role of mitochondria in this process. Toxicol. Lett. (2012) 208 36-40.
39. 2+ induces permeability transition pore opening and release of pro-apoptotic peptides from neuronal mitochondria. J. Biol. Chem. (2001) 276 47524-47529.
40. de Souza L.C., Sarazin M., Teixeira Junior A.L. et al. Biological markers of Alzheimers disease. Arq. Neuropsiquiatr. (2014) 72 227-231.
41. Faller P., Hureau C., Berthoumieu O. Role of metal ions in the self-assembly of the Alzheimer's amyloid-beta peptide. Inorg. Chem. (2013) 52 12193-12206.
42. Szewczyk B. Zinc homeostasis and neurodegenerative disorders. Front. Aging Neurosci. (2013) 5 33.
43. Stefanidou M., Maravelias C., Dona A., Spiliopoulou C. Zinc: a multipurpose trace element. Arch. Toxicol. (2006) 80 1-9.
44. Adlard P.A., Parncutt J.M., Finkelstein D.I., Bush A.I. Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J. Neurosci. (2010) 30 1631-1636.
45. Poewe W. Non-motor symptoms in Parkinson's disease. Eur. J. Neurol. (2008) 15 14-20.
46. Camilleri A., Vassallo N. The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease. CNS Neurosci. Ther. (2014) 20 591-602.
47. Malek N., Swallow D., Grosset K.A., Anichtchik O., Spillantini M., Grosset D.G. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. Acta Neurol. Scand. (2014) 130 59-72.
48. Greene J.G., Dingledine R., Greenamyre J.T. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol. Dis. (2005) 18 19-31.
49. Hochstrasser T., Hohsfield L.A., Sperner-Unterweger B., Humpel C. Beta-Amyloid induced effects on cholinergic, serotonergic, and dopaminergic neurons is differentially counteracted by anti-inflammatory drugs. J. Neurosci. Res. (2013) 91 83-94.
50. Ma K.L., Song L.K., Yuan Y.H. et al. α-Synuclein is Prone to Interaction with the GC-Box-Like Sequence In Vitro. Cell. Mol. Neurobiol. (2014) 34 603-609.
51. Mander P.K., Jekabsone A., Brown G.C. Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase. J. Immunol. (2006) 176 1046-1052.
52. Park K.W., Baik H.H., Jin B.K. Interleukin-4-induced oxidative stress via microglial NADPH oxidase contributes to the death of hippocampal neurons in vivo. Curr. Aging Sci. (2008) 1 192-201.
53. Park K.W., Baik H.H., Jin B.K. IL-13-induced oxidative stress via microglial NADPH oxidase contributes to death of hippocampal neurons in vivo. J. Immunol. (2009) 183 4666-4674.
54. Hozumi I., Hasegawa T., Honda A. et al. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J. Neurol. Sci. (2011) 303 95-99.
55. Donnan G.A., Fisher M., Macleod M., Davis S.M. Stroke. Lancet (2008) 371 1612-1623.
56. NINDS Brain basics: preventing stroke. National institute of Neurological Disorders and stroke. Bethesda, Maryland, USA, 2011.
57. Kandel E.R., Schwartz J.H., Jessell T.M. Principles of neural science, 4th edn, McGraw-Hill, Health Professions Division, New York, 2000.
58. Deb P., Sharma S., Hassan K.M. Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology (2010) 17 197-218.
59. Bendok B.R. Hemorrhagic and ischemic stroke: surgical, interventional, imaging and medical approaches. Thieme Medical Publishers, New York, 2011.
60. Bohic S., Ghersi-Egea J.F., Gibon J. et al. Biological roles of trace elements in the brain with special focus on Zn and Fe. Rev. Neurol. (Paris) (2011) 167 269-279.
61. Stork C.J., Li Y.V. Rising zinc: a significant cause of ischemic neuronal death in the CA1 region of rat hippocampus. J. Cereb. Blood Flow Metab. (2009) 29 1399-1408.
62. Colvin R.A., Holmes W.R., Fontaine C.P., Maret W. Cytosolic zinc buffering and muffling: their role in intracellular zinc homeostasis. Metallomics (2010) 2 306-317.
63. Stork C.J., Li Y.V. Zinc release from thapsigargin/IP3-sensitive stores in cultured cortical neurons. J. Mol. Signal. (2010) 5 5.
64. Medvedeva Y.V., Lin B., Shuttleworth C.W., Weiss J.H. Intracellular zinc accumulation contributes to synaptic failure, mitochondrial depolarization, and cell death in an acute slice oxygen-glucose deprivation model of ischemia. J. Neurosci. (2009) 29 1105-1114.
65. Calderone A., Jover T., Mashiko T. et al. Late calcium EDTA rescues hippocampal CA1 neurons from global ischemia-induced death. J. Neurosci. (2004) 24 9903-9913.
66. Gazaryan I.G., Krasinskaya I.P., Kristal B.S., Brown A.M. Zinc irreversibly damages major enzymes of energy production and antioxidant defense prior to mitochondrial permeability transition. J. Biol. Chem. (2007) 282 24373-24380.
67. Shahbaz A.U., Zhao T., Zhao W. et al. Calcium and zinc dyshomeostasis during isoproterenol-induced acute stressor state. Am. J. Physiol. Heart Circ. Physiol. (2011) 300 H636-H644.
68. Stanika R.I., Winters C.A., Pivovarova N.B., Andrews S.B. Differential NMDA receptor-dependent calcium loading and mitochondrial dysfunction in CA1 vs. CA3 hippocampal neurons. Neurobiol. Dis. (2010) 37 403-411.
69. Liao S.L., Ou Y.C., Lin S.Y. et al. Signaling cascades mediate astrocyte death induced by zinc. Toxicol. Lett. (2011) 204 108-117.
70. Qu Z.W., Miao W.Y., Hu S.Q., Li C. et al. N-methyl-D-aspartate receptor-dependent denitrosylation of neuronal nitric oxide synthase increase the enzyme activity. PLoS One (2012) 7 e52788.
71. Blanco-Alvarez V.M., Lopez-Moreno P., Soto-Rodriguez G. et al. Subacute zinc administration and L-NAME caused an increase of NO, zinc, lipoperoxidation, and caspase-3 during a cerebral hypoxia-ischemia process in the rat. Oxid. Med. Cell Longev. (2013) 2013 240560.
72. McCranor B.J., Bozym R.A., Vitolo M.I. et al. Quantitative imaging of mitochondrial and cytosolic free zinc levels in an in vitro model of ischemia/reperfusion. J. Bioenerg. Biomembr. (2012) 44 253-263.
73. Languren G., Montiel T., Julio-Amilpas A., Massieu L. Neuronal damage and cognitive impairment associated with hypoglycemia: an integrated view. Neurochem. Int. (2013) 63 331-343.
74. Lee J.Y., Kim Y.J., Kim T.Y., Koh J.Y., Kim Y.H. Essential role for zinc-triggered p75NTR activation in preconditioning neuroprotection. J. Neurosci. (2008) 28 10919-10927.
75. Lei C., Lin S., Zhang C. et al. Activation of cerebral recovery by matrix metalloproteinase-9 after intracerebral hemorrhage. Neuroscience (2013) 230 86-93.
76. He T., Katusic Z.S. Brain-derived neurotrophic factor increases expression of MnSOD in human circulating angiogenic cells. Microvasc. Res. (2012) 83 366-371.
77. Leng T., Shi Y., Xiong Z.G., Sun D. Proton-sensitive cation channels and ion exchangers in ischemic brain injury: new therapeutic targets for stroke? Prog. Neurobiol. (2014) 115C 189-209.
78. Nolan K., Mitchem M.R., Jimenez-Mateos E.M., Henshall D.C. et al. Increased expression of microRNA-29a in ALS mice: functional analysis of its inhibition. J. Mol. Neurosci. (2014) 53 231-241.
79. Rosen D.R., Siddique T., Patterson D. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362 59?62.
80. Homma K., Fujisawa T., Tsuburaya N. SOD1 as a molecular switch for initiating the homeostatic ER stress response under zinc deficiency. Mol. Cell (2013) 52 75-86.
81. Turner B.J., Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. (2008) 85 94-134.
82. Soto C., Estrada L.D. Protein misfolding and neurodegeneration. Arch. Neurol. (2008) 65 184-189.
83. Chattopadhyay M., Durazo A., Sohn S.H. et al. Initiation and elongation in fibrillation of ALS-linked superoxide dismutase. Proc. Natl Acad. Sci. USA (2008) 105 18663-18668.
84. Wang J., Farr G.W., Zeiss C.J. et al. Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. Proc. Natl Acad. Sci. USA (2009) 106 1392-1397.
85. Tiwari A., Hayward L.J. Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. J. Biol. Chem. (2003) 278 5984-5992.
86. Paoletti P., Vergnano A.M., Barbour B., Casado M. Zinc at glutamatergic synapses. Neuroscience (2008) 15 15.
87. Inoue K., Branigan D., Xiong Z.G. Zinc-induced neurotoxicity mediated by transient receptor potential melastatin 7 channels. J. Biol. Chem. (2010) 285 7430-7439.
88. Viles J.H., Klewpatinond M., Nadal R.C. Copper and the structural biology of the prion protein. Biochem. Soc. Trans. (2008) 36 1288-1292.
89. Salès N., Rodolfo K., Hässig R., Faucheux B., Di Giamberardino L., Moya K.L. Cellular prion protein localization in rodent and primate brain. Eur. J. Neurosci. (1998) 10 2464-2471.
90. Frederickson C.J., Bush A.I. Synaptically released zinc: physiological functions and pathological effects. Biometals (2001) 14 353-366.
91. Watt N.T., Hooper N.M. The prion protein and neuronal zinc homeostasis. Trends Biochem. Sci. (2003) 28 406-410.
92. 2+ coordination modes. J. Am. Chem. Soc. (2007) 129 15440-15441.
93. Perera W.S., Hooper N.M. Ablation of the metal ion-induced endocytosis of the prion protein by disease-associated mutation of the octarepeat region. Curr. Biol. (2001) 11 519-523.
94. Watt N.T., Taylor D.R., Kerrigan T.L. et al. Prion protein facilitates uptake of zinc into neuronal cells. Nat. Commun. (2012) 3 1134.
95. Taylor D.R., Hooper N.M. The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochem. J. (2007) 402 17-23.
96. Wong B.S., Chen S.G., Colucci M. et al. Aberrant metal binding by prion protein in human prion disease. J. Neurochem. (2001) 78 1400-1408.
97. Linden R., Martins V.R., Prado M.A., Cammarota M., Izquierdo I., Brentani R.R. Physiology of the prion protein. Physiol. Rev. (2008) 88 673-728.
98. Spevacek A.R., Evans E.G., Miller J.L., Meyer H.C., Pelton J.G., Millhauser G.L. Zinc drives a tertiary fold in the prion protein with familial disease mutation sites at the interface. Structure (2013) 21 236-246.
99. Kenward A.G., Bartolotti L.J., Burns C.S. et al. Copper and zinc promote interactions between membrane-anchored peptides of the metal binding domain of the prion protein. Biochemistry (2007) 46 4261-4271.
100. Takeda A. Movement of zinc and its functional significance in the brain. Brain Res. Bull. (2000) 34 137-148.
101. Wang Z., Li J.Y., Dahlstrom A., Danscher G. Zinc-enriched GABAergic terminals in mouse spinal cord. Brain Res. (2001) 921 165-172.
102. Frederickson C.J., Moncrieff D.W. Zinc-containing neurons. Biol. Signals (1994) 3 127-139.
103. Frederickson C.J., Suh S.W., Silva D., Frederickson C.J., Thompson R.B. Importance of zinc in the central nervous system: the zinc-containing neuron. J. Nutr. (2000) 130 1471S-1483S.
104. Takeda A., Tamano H. Insight into zinc signaling from dietary zinc deficiency. Brain Res. Rev. (2009) 62 33-34.
105. Liuzzi J.P., Cousins R.J. Mammalian zinc transporters. Annu. Rev. Nutr. (2004) 24 151-172.
106. Nowak G., Zieba A., Dudek D. et al. Serum trace elements in animal models and human depression. Part I. Zinc. Hum. Psychopharmacol. (1999) 14 83-86.
107. Wojcik J., Dudek D., Schlegiel-Zawadzka M. et al. Antepartum/postpartum depressive symptoms and serum zinc and magnesium levels. Pharmacol. Rep. (2006) 58 571-576.
108. Schlegel-Zawadzka M., Zieba A., Dudek D., Krosniak M., Szymaczek M., Nowak G. Effect of depression and of antidepressant therapy on serum zinc levels-a preliminary clinical study, in: Roussel A.M., Anderson R.A., Favrier A.E. (Eds), Trace elements in man and animals 10. Kluwer Academic Plenum Press, New York, 2000, pp. 607-610.
109. Nowak G., Siwek M., Dudek D., Zieba A., Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol. J. Pharmacol. (2003a) 55 1143-1147.
110. Suh S.W., Won S.J., Hamby A.M. et al. Decreased brain zinc availability reduces hippocampal neurogenesis in mice and rats. J. Cereb. Blood Flow Metab. (2009) 29 1579-1588.
111. Gao H.L., Zheng W., Xin N. et al. Zinc deficiency reduces neurogenesis accompanied by neuronal apoptosis through caspase-dependent and -independent signaling pathways. Neurotox. Res. (2009) 16 416-425.
112. Corniola R.S., Tassabehji N.M., Hare J., Sharma G., Levenson C.W. Zinc deficiency impairs neuronal precursor cell proliferation and induces apoptosis via p53-mediated mechanisms. Brain Res. (2008) 1237 52-61.
113. Tassabehji N.M., Corniola R.S., Alshingiti A., Levenson C.W. Zinc deficiency induces depression-like symptoms in adult rats. Physiol. Behav. (2008) 95 365-369.
114. Sen S., Sanacora G. Major depression: emerging therapeutics. Mt Sinai J. Med. (2008) 75 204-225.
115. Takeda A., Kanno S., Sakurada N., Ando M., Oku N. Attenuation of hippocampal mossy fiber long-term potentiation of low micromolar concentrations of zinc. J. Neurosci. Res. (2008a) 86 2909-2911.
116. Howland J.G., Wang Y.T. Synaptic plasticity in learning and memory: stress effects in the hippocampus. Prog. Brain Res. (2008) 169 145-158.
117. Mocchegiani E., Freddari C.B., Marcellini F., Malavota M. Brain, aging and neurodegeneration: role of zinc ion availability. Prog. Neurobiol. (2005) 75 367-390.
118. Smart T.G., Xie X., Krishek B.J. Modulation of inhibitory and excitatory amino acid receptor ion channels by zinc. Prog. Neurobiol. (1994) 42 393-441.
119. Takeda A., Minami A., Seki Y., Oku N. Differential effects of zinc on glutamatergic and GABAergic neurotransmitter systems in the hippocampus. J. Neurosci. Res. (2004) 75 225-229.
120. Ebadi M., Murrin L.C., Pfeiffer R.F. Hippocampal zinc thionein and pyridoxal phosphate modulate synaptic functions. Ann. N. Y. Acad. Sci. (1990) 585 189-201.
121. Zirpel L., Parks T.N. Zinc inhibition of group I mGluR-mediated calcium homeostasis in auditory neurons. J. Assoc. Res. Otolaryngol. (2001) 2 180-187.
122. 2+: an endogenous modulator of ligand- and voltage-gated ion channels. Neuropharmacology (1994) 33 935-952.
123. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med. (2004) 5 11-25.
124. Castren E., Voikar V., Rantamaki T. Role of neurotrophic factors in depression. Curr. Opin. Pharmacol. (2007) 7 18-21.
125. Lee E., Son H. Adult hippocampal neurogenesis and related neurotrophic factors. BMB Rep. (2009) 42 239-244.
126. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav. Pharmacol. (2007) 18 391-418.
127. Dwivedi Y., Mondal A.C., Rizavi H.S., Conley R.R. Suicide brain is associated with decreased expression of neurotrophins. Biol. Psychiatry (2005) 58 315-324.
128. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. (1980) 107 519-527.
129. Giese K.P. GSK-3: a key player in neurodegeneration and memory. IUBMB Life (2009) 61 516-521.
130. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK-3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets (2006) 7 1421-1434.
131. Gould T.D., Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 30 1223-1237.
132. Ilouz R., Kaidanovich O., Gurwitz D., Finkelman-Eldar H. Inhibition of glycogen synthase kinase-3β by divalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem. Biophys. Res. Commun. (2002) 295 102-106.
133. Szewczyk B., Poleszak E., Wlaz P. et al. The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog. Neuropsychopharmacol. Biol. Psychiatry (2009) 33 323-329.
134. Cunha M.P., Machado D.G., Bettio L.E., Capra J.C., Rodrigues A.L. Interaction of zinc with antidepressants in tail suspension test. Prog. Neuropsychopharmacol. Biol. Psychiatry (2008) 32 1913-1920.
135. Barrondo S., Salles J. Allosteric modulation of 5-HT(1A) receptors by zinc: binding studies. Neuropharmacology (2009) 56 455-462.
136. Pompeiano M., Palacios J.M., Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. (1992) 12 440-453.
137. Bremmer M.A., Beekman A.T., Deeg D.J. et al. Inflammatory markers in late-life depression: results from a population-based study. J. Affect. Disord. (2008) 106 249-255.
138. Nowak G., Kubera M., Maes M. Neuroimmunological aspects of the alterations in zinc homeostasis in pathophysiology and treatment of depression. Acta Neuropsychiatr. (2000) 12 49-53.
139. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry (2007) 12 988-1000.
140. Myint A.M., Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses (2003) 61 519-525.
141. Fedele E., Foster A.C. An evaluation of the role of extracellular amino acids in the delayed (1-59) neurodegeneration induced by quinolinic acid in the rat striatum. Neuroscience (1993) 52 911-917.
142. Walker F.O. Huntington's disease. Semin. Neurol. (2007) 27 143-150.
143. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. (2007) 83 228-248.
144. Kumar P., Kalonia H., Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol. Rep. (2010) 62 1-14.
145. Ramaswamy S., Kordower J.H. Gene therapy for Huntington's disease. Neurobiol. Dis. (2012) 48 243-254.
146. Sharp A.H., Loev S.J., Schilling G. et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron (1995) 4 1065-1074.
147. Duyao M.P. et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science (1995) 269 407-410.
148. Dragatsis I., Levine M.S., Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. (2000) 26 300-306.
149. Pfister E.L. et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. (2009) 19 774-778.
150. Klug A. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu. Rev. Biochem. (2010) 79 213-231.
151. Mittelman D. et al. Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc. Natl Acad. Sci. USA (2009) 106 9607-9612.
152. Bitanihirwe B.K., Cunningham M.G. Zinc: the brain's dark horse. Synapse (2009) 63 1029-1049.
153. Frederickson C.J. Neurobiology of zinc and zinc-containing neurons. Int. Rev. Neurobiol. (1989) 31 145-238.
154. Chorin E., Vinograd O., Fleidervish I., Gilad D., Herrmann S. et al. Upregulation of KCC2 activity by zinc-mediated neurotransmission via the mZnR/GPR39 receptor. J. Neurosci. (2011) 31 12916-12926.
155. Minami A., Sakurada N., Fuke S., Kikuchi K., Nagano T. et al. Inhibition of presynaptic activity by zinc released from mossy fiber terminals during titanic stimulation. J. Neurosci. Res. (2006) 83 167-176.
156. Elsas S.M., Hazany S., Gregory W.L., Mody I. Hippocampal zinc infusion delays the development of after discharges and seizures in a kindling model of epilepsy. Epilepsia (2009) 50 870-879.
157. Seyfried T.N., Glaser G.H. A review of mouse mutants as genetic models of epilepsy. Epilepsia (1985) 26 143-150.
158. Wagner E., Rosati M., Molin J. et al. Hippocampal sclerosis in feline epilepsy. Brain Pathol. (2014) 24 607-619.
159. During M.J., Spencer D.D. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet (1993) 341 1607-1610.
160. Sensi S.L., Paoletti P., Koh J.Y., Aizenman E., Bush A.I. et al. The neurophysiology and pathology of brain zinc. J. Neurosci. (2011) 31 16076-16085.
161. Baraka A.M., Hassab El Nabi W., El Ghotni S. Investigating the role of zinc in a rat model of epilepsy. CNS Neurosci. Ther. (2012) 18 327-333.
162. Yorulmaz H., Seker F.B., Demir G. et al. The effects of zinc treatment on the blood-brain barrier permeability and brain element levels during convulsions. Biol. Trace Elem. Res. (2013) 151 256-262.
163. Cole T., Robbins C., Wenzel H., Schwartzkroin P., Palmiter R. Seizures and neuronal damage in mice lacking vesicular zinc. Epilepsy Res. (2000) 39 153-169.
164. Qian J., Xu K., Yoo J. et al. Knockout of Zn transporters Zip-1 and Zip-3 attenuates seizure-induced CA1 neurodegeneration. J. Neurosci. (2011) 31 97-104.
165. 2+. Proc. Natl Acad. Sci. USA (2009) 106 8374-8379.
166. Takeda A., Iida M., Ando M. et al. Enhanced susceptibility to spontaneous seizures of noda epileptic rats by loss of synaptic Zn(2+). PLoS One (2013) 8 e71372.
167. Kim J.H., Jang B.G., Choi B.Y. et al. Zinc chelation reduces hippocampal neurogenesis after pilocarpine-induced seizure. PLoS One (2012) 7 e48543.
168. Faul M., Xu L., Wald M.M., Coronado V.G. Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002-2006. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, 2010.
169. Terrio H., Brenner L.A., Ivins B.J. et al. Traumatic brain injury screening: preliminary findings in a US Army Brigade Combat Team. J. Head Trauma Rehabil. (2009) 24 14-23.
170. Jorge R.E., Starkstein S.E. Pathophysiologic aspects of major depression following traumatic brain injury. J. Head Trauma Rehabil. (2005) 20 475-487.
171. Morris D.R., Levenson C.W. Zinc in traumatic brain injury: from neuroprotection to neurotoxicity. Curr. Opin. Clin. Nutr. Metab. Care (2013) 16 708-711.
172. Doering P., Stoltenberg M., Penkowa M., Rungby J., Larsen A., Danscher G. Chemical blocking of zinc ions in CNS increases neuronal damage following traumatic brain injury (TBI) in mice. PLoS One (2010) 5 e10131.
173. Li Y., Hawkins B.E., DeWitt D.S., Prough D.S., Maret W. The relationship between transient zinc ion fluctuations and redox signaling in the pathways of secondary cellular injury: relevance to traumatic brain injury. Brain Res. (2010) 1330 131-141.
174. Cope E.C., Morris D.R., Scrimgeour A.G. et al. Zinc supplementation provides behavioral resiliency in a rat model of traumatic brain injury. Physiol. Behav. (2011) 104 942-947.
175. Cope E.C., Morris D.R., Scrimgeour A.G. et al. Use of zinc as a treatment for traumatic brain injury in the rat: effects on cognitive and behavioral outcomes. Neurorehabil. Neural Repair (2012) 26 907-913.
176. Vidović B., Dordević B., Milovanović S. et al. Selenium, zinc, and copper plasma levels in patients with schizophrenia: relationship with metabolic risk factors. Biol. Trace Elem. Res. (2013) 156 22-28.
177. Tyszka-Czochara M., Grzywacz A., Gdula-Argasińska J., Librowski T., Wiliński B., Opoka W. The role of zinc in the pathogenesis and treatment of central nervous system (CNS) diseases. Implications of zinc homeostasis for proper CNS function. Acta Pol. Pharm. (2014) 71 69-77.
178. Michel T.M., Thome J., Martin D. et al. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenicpsychosis. J. Neural. Transm. (2004) 111 1191-1201.
179. Joshi M., Akhtar M., Najmi A.K., Khuroo A.H., Goswami D. Effect of zinc in animal models of anxiety, depression and psychosis. Hum. Exp. Toxicol. (2012) 31 1237-1243.
180. Hollister L.E. Biochemical theories of schizophrenia and depression. Ann. Acad. Med. Singapore (1985) 14 76-80.
181. Hoogenraad T.U., Van den Hamer C.J., Koevoet R., Korver E.G. Oral zinc in Wilson's disease. Lancet (1978) 2 1262.